Treatment options for

metastatic urothelial carcinoma:

eLearning activities

Publication date: 11 May 2022

Accreditation expiration date: 11 May 2023

Esitimated time to complete: 15 minutes

Activity 1: Immunotherapy options in first-line and maintenance therapy for patients with mUC

In this eLearning video module, Marc-Oliver Grimm will outline available and emerging immunotherapy options in first-line for patients with metastatic UC and describe the potential of immunotherapy in the maintenance setting, as well as analyze the clinical data supporting these strategies.

Learning objectives

After completing this activity, you will be able to:

Discuss available and emerging immunotherapy options in first-line for patients with mUC
Interpret clinical data behind these options and understand how it can impact clinical practice
Describe the potential of immunotherapy in the maintenance setting

Login to access this activity

No account? Create a free account now

Email*
Password*
Enter Password Confirm Password
Healthcare Professional*
(Required) I confirm that I am a healthcare professional*
Privacy Acceptance*
(Required) I have read and accept the terms of the Privacy notice and the Terms and Conditions and consent to receive e-alerts from Springer Healthcare IME pertinent to my area of interest. I can withdraw my consent at any time by contacting IME@springer.com or via the ‘unsubscribe’ link included in any email communications*
SHE Communication Preferences
(Optional) I agree that my email address will be used by our sister site Medicine Matters Oncology, as per their Privacy Policy, for the purposes of communicating to me details of educational content pertinent to Oncology. I can withdraw my consent at any time by contacting medicinematters@springer.com or via the ‘unsubscribe’ link included in any email communications.
Comments
This field is for validation purposes and should be left unchanged.

Module Content

Sections Status